Zobrazeno 1 - 10
of 309
pro vyhledávání: '"Eric J. Sherman"'
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Sarin Kitpanit, Anna Lee, Ken L. Pitter, Dan Fan, James C.H. Chow, Brian Neal, Zhiqiang Han, Pamela Fox, Kevin Sine, Dennis Mah, Lara A. Dunn, Eric J. Sherman, Loren Michel, Ian Ganly, Richard J. Wong, Jay O. Boyle, Marc A. Cohen, Bhuvanesh Singh, Cameron W. Brennan, Igor T. Gavrilovic, Vaios Hatzoglou, Bernard O‘Malley, Kaveh Zakeri, Yao Yu, Linda Chen, DaphnaY. Gelblum, Jung Julie Kang, Sean M. McBride, Chiaojung J. Tsai, Nadeem Riaz, Nancy Y. Lee
Publikováno v:
International Journal of Particle Therapy, Vol 6, Iss 4, Pp 1-12 (2020)
Purpose: To demonstrate temporal lobe necrosis (TLN) rate and clinical/dose-volume factors associated with TLN in radiation-naïve patients with head and neck cancer treated with proton therapy where the field of radiation involved the skull base. Ma
Externí odkaz:
https://doaj.org/article/13629738ba634f5f937500601396273a
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/5da51ab03db947f7a3ffd0a6118bb43a
Autor:
Tony K W Hung, Gilad J Kuperman, Eric J Sherman, Alan L Ho, Chunhua Weng, David G Pfister, Jun J Mao
Publikováno v:
Journal of Medical Internet Research, Vol 26, p e60695 (2024)
Externí odkaz:
https://doaj.org/article/4ee9c132db9943aa8e717d27fd60e408
Autor:
Eric J Sherman, Jonathan Harris, Keith C Bible, Ping Xia, Ronald A Ghossein, Christine H Chung, Nadeem Riaz, G Brandon Gunn, Robert L Foote, Sue S Yom, Stuart J Wong, Shlomo A Koyfman, Michael F Dzeda, David A Clump, Saad A Khan, Manisha H Shah, Kevin Redmond, Pedro A Torres-Saavedra, Quynh-Thu Le, Nancy Y Lee
Publikováno v:
The Lancet Oncology. 24:175-186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbd668ad9f325a065208d2b64a751ce2
https://doi.org/10.1016/s1470-2045(22)00763-x
https://doi.org/10.1016/s1470-2045(22)00763-x
Autor:
Ian Ganly, Timothy A. Chan, Ronald Ghossein, Bin Xu, Eric J. Sherman, James A. Fagin, Rui Qu, Huiyong Zhao, Omer Aras, Gouri J. Nanjangud, Ed Reznik, Vladimir Makarov, Fengshen Kuo, Yongxing Gong, Yiyu Dong
Combination treatment with rapamycin and lenvatinib in PDX model TC1m1. A, Combination treatment resulted in enhanced decrease in CD31 staining endothelial vessels compared to lenvatinib alone or rapamycin alone. B, The average IMVD values of CD31 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dabc040d6ab10bff6dcf98b06241993
https://doi.org/10.1158/1535-7163.22522548
https://doi.org/10.1158/1535-7163.22522548
Autor:
David M. Hyman, Bethany Pitcher, Todd Riehl, Eric J. Sherman, Gregory J. Riely, Eli L. Diamond, Jason Roszik, Funda Meric-Bernstam, José Baselga, Juergen Wolf, Noopur S. Raje, A. Craig Lockhart, Ian Chau, Jean-Yves Blay, Igor Puzanov, Vivek Subbiah
Supplementary figures 1 & 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352b7e195351285e41e52d749735d71c
https://doi.org/10.1158/2159-8290.22535063
https://doi.org/10.1158/2159-8290.22535063
Autor:
James A. Fagin, Neal Rosen, Ronald A. Ghossein, Mabel Ryder, Eric J. Sherman, Agnes Viale, Jeffrey A. Knauf, Jose M. Dominguez, Sergio Ruiz-Llorente, Cristina Montero-Conde
Supplementary Figure S5 PDF file - 32K, PLX4032 decreases occupancy of the HER3 gene promoter in SW1736 thyroid cancer cells. A, CtBP1 or CtBP2 chromatin immunoprecipitation assays were performed in SW1736 cells treated with or without 2 ��M PLX4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0200ad97f0ee46a8ebc5c53106262ce5
https://doi.org/10.1158/2159-8290.22529378.v1
https://doi.org/10.1158/2159-8290.22529378.v1
Autor:
Luc G.T. Morris, James A. Fagin, Timothy A. Chan, Alan L. Ho, Eric J. Sherman, Richard J. Wong, Snjezana Dogan, Vladimir Makarov, Neal Patel, Zaineb Nadeem, Cristina Valero, Fengshen Kuo, Catherine Han, Ronald Ghossein, Bin Xu, Brian R. Untch, Mark Lee
Targeted inhibition of BRAF V600E achieves tumor control in a subset of advanced thyroid tumors. Nearly all tumors develop resistance, and some have been observed to subsequently undergo dedifferentiation. The molecular alterations associated with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dff8eee2d1cfea9be68c75d008bf1a6
https://doi.org/10.1158/1541-7786.c.6545222
https://doi.org/10.1158/1541-7786.c.6545222
Autor:
David M. Hyman, Bethany Pitcher, Todd Riehl, Eric J. Sherman, Gregory J. Riely, Eli L. Diamond, Jason Roszik, Funda Meric-Bernstam, José Baselga, Juergen Wolf, Noopur S. Raje, A. Craig Lockhart, Ian Chau, Jean-Yves Blay, Igor Puzanov, Vivek Subbiah
BRAFV600 mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers. Despite this progress, BRAFV600 mutations have historically been considered a clear demonstration of tumor lineage context–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b7a921d27c9d3f8082e6fbbe95a137e
https://doi.org/10.1158/2159-8290.c.6547751.v1
https://doi.org/10.1158/2159-8290.c.6547751.v1